

## Diabetic Retinopathy Guideline Post-Consultation Committee Meeting

**Date:** 20<sup>th</sup> October 2023  
**Location:** Virtual Meeting via Zoom  
**Minutes:** Final

<b>Committee members present:</b>		
Mike Burdon (Chair)		Present for all items
John Anderson		Present for all items
Amandeep Bedi		Present for all items
Philip Burgess		Present for all items
Rosalind Creer		Present for all items
Julie Davey		Present for all items
Christiana Dinah		Present for all items
Noemi Lois		Present for all items
Louis Savage		Present for all items
Diva Shah		Present for all items
Lloyd Thomas		Present for all items
Bernadette Warren		Present for all items
Becky Wei Luo		Present for all items

<b>In attendance:</b>		
Astrid Aregui (AA)	Senior Medical Editor, NICE	Present for all items
Catrina Charlton	Guideline Commissioning Manager, NICE	Present for all items
Clare Dadswell (CD)	Senior Technical Analyst	Present for all items
Jon Littler (JL)	Project Manager, Guideline Development Team	Present for all items
Syed Mohiuddin (SM)	Technical Adviser (Health Economics)	Present for all items
Katrina Penman	Technical Adviser – observing	Present for all items
Hannah Tebbs	Senior Health Economist	Present for all items
Philip Williams	NICE Resource Impact Lead	Present for all items
Ahmed Yosef (AY)	Technical Analyst, Guideline Development Team	Present for all items

<b>Apologies:</b>		

## Diabetic Retinopathy guideline committee minutes 20th October 2023

### 1. Welcome and DOIs for the meeting

The Chair welcomed the committee members and attendees to the final meeting on Diabetic Retinopathy. The committee members and attendees introduced themselves. The Chair informed the Committee that no apologies had been received for this meeting.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Diabetic Retinopathy. The Chair asked everyone to verbally declare any new interests that were not listed in the registry. The following interests were declared:

Member	Role on Committee	Interest	Decision
Phillip Burgess	Consultant Ophthalmologist	Speaker at a King's Fund event sponsored by Roche. Presentation was on collecting data from people with diabetes and diabetic retinopathy but not condition management. Travel and accommodation covered.	Declare and participate. Rationale: Since the focus was on data collection and not treatment/management, this interest is not in scope.
Christiana Dinah	Consultant Ophthalmologist	Johnson and Johnson Limited – Consultant advisor for geographic atrophy program	Declare and participate. Rationale: Not specific to the scope of the guideline. There is no current treatment for GA in the UK.
Christiana Dinah	Consultant Ophthalmologist	Boehringer Ingelheim - Consultant advisor for geographic atrophy clinical trials and women in retina program	Declare and participate. Rationale: Not specific to the scope of the guideline. There is no current treatment for GA in the UK.
Louis Savage	General Practitioner	Standing Member, NICE Quality Standards Advisory Committee	Declare and participate. Rationale: Work on NICE quality standards presents no conflict with NICE clinical guidelines.

The Chair and development team agreed that none of these newly declared interests were a barrier to the relevant members attending and contributing to the meeting and the Chair moved on to the next item on the agenda.

### 2. Responding to stakeholder consultation comments – health economics and VEGF phrasing

The Chair introduced Hannah Tebbs (HT), Senior Health Economist and Syed Mohiuddin (SM), Health Economic Adviser who guided the committee through the stakeholder comments the consultation had received. Specifically, those that impacted the economic models they had created and the report they'd drawn up. HT and SM offered the committee their suggested responses to comments and the

## Diabetic Retinopathy guideline committee minutes 20th October 2023

committee offered their feedback on how to make relevant changes and refine the responses where changes were (or were not) made.

Additionally, SM and HT queried the committee on the best way to change the phrasing around anti-VEGF recommendations in light of stakeholder queries.

The Chair thanked the committee for their suggestions, and HT and SM for their work in preparing their data and presentation and moved the discussion on to the next agenda item.

### **3. Responding to stakeholder consultation comments – clinical comments and monitoring PDR recommendations**

For the next item on the agenda, the Chair introduced Ahmed Yosef (AH), Technical Analyst and Clare Dadswell (CD), Senior Technical Analyst, who took the committee through the stakeholder comments on our clinical recommendations.

During this section, committee member Noemi Lois was briefly asked to step out of the meeting due to a conflict around Monitoring PDR.

AH and CD presented the committee with the comments received from stakeholder organisations on our clinical recommendations, along with our suggested changes/responses. The committee gave their opinions and suggestions on how recommendations could change in light of certain comments, and how stakeholders could be responded to, before the Chair called a halt to the morning session and broke for lunch.

### **4. Responding to stakeholder consultation comments – terminology, definitions and DMO recommendations.**

AH and CD were also presenting for this agenda item, and in this instance, Christiana Dinah briefly stepped out of the committee due to a conflict of interest she has in the area of diabetic macular oedema.

As before, AH and CD presented the committee with the comments received from stakeholder organisations on our clinical recommendations, specifically around DMO, along with our suggested changes/responses. The committee gave their feedback, which the Chair thanked them for, before moving the meeting to its penultimate item.

### **5. General comments**

For the penultimate item on the agenda, AH and CD presented the general comments from stakeholders on our clinical recommendations, asking once again for feedback in how the wording or recommendations could be adjusted if appropriate, or how the comment could be responded to.

After receiving final comments and suggestions from the committee, the Chair thanked everyone and moved the meeting to the final item of the day.

### **6. AOB, summary and next steps**

The Chair thanked the committee and the NICE team for the hard work they had put in on development

## Diabetic Retinopathy guideline committee minutes 20th October 2023

so far. He then introduced Jon Littler (JL), Project Manager, who advised the committee of the next steps of the guideline.

JL gave the committee an overview of the timeline for the guideline over the coming months, up to and including the publication date of 2<sup>nd</sup> February 2024. He then advised them that the development team would spend the next week working on the recommendations and stakeholder responses before sending them out to the committee for final comments on Friday 27<sup>th</sup> October. He advised that all members were still subject to confidentiality between now and the publication of this guideline and to keep him apprised of any updates to their potential conflicts of interest.

The Chair then thanked everyone for their work and contributions to what was a long day of discussions and concluded the meeting.